DELMONTE, ANNAMARIA
DELMONTE, ANNAMARIA
Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3)
2021 Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A.
ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)
2020 Chiari R.; Ricciuti B.; Landi L.; Morelli A.M.; Delmonte A.; Spitaleri G.; Cortinovis D.L.; Lamberti G.; Facchinetti F.; Pilotto S.; Verusio C.; Chella A.; Bonanno L.; Galetta D.; Cappuzzo F.
BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience
2019 Rihawi K ; Giannarelli D ; Galetta D ; Delmonte A ; Giavarra M ; Turci D ; Garassino M ; Tiseo M ; Barbieri ; Panni S ; Ardizzoni A;
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population
2019 Crino, L.; Bidoli, P.; Delmonte, A.; Grossi, F.; De Marinis, F.; Ardizzoni, A.; Vitiello, F.; Lo Russo, G.; Parra, H. S.; Cortesi, E.; Cappuzzo, F.; Calabro, L.; Tiseo, M.; Turci, D.; Gamucci, T.; Antonelli, P.; Morabito, A.; Chella, A.; Giannarelli, D.; Galetta, D.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3) | Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo ...L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A. | 2021-01-01 | BRITISH JOURNAL OF CANCER | - | 1.04 Replica / breve intervento (e simili) | - |
| ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS) | Chiari R.; Ricciuti B.; Landi L.; Morelli A.M.; Delmonte A.; Spitaleri G.; Cortinovis D.L.; Lambe...rti G.; Facchinetti F.; Pilotto S.; Verusio C.; Chella A.; Bonanno L.; Galetta D.; Cappuzzo F. | 2020-01-01 | CLINICAL LUNG CANCER | - | 1.01 Articolo in rivista | - |
| BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience | Rihawi K ; Giannarelli D ; Galetta D ; Delmonte A ; Giavarra M ; Turci D ; Garassino M ; Tiseo M... ; Barbieri ; Panni S ; Ardizzoni A; | 2019-01-01 | JOURNAL OF THORACIC ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population | Crino, L.; Bidoli, P.; Delmonte, A.; Grossi, F.; De Marinis, F.; Ardizzoni, A.; Vitiello, F.; Lo ...Russo, G.; Parra, H. S.; Cortesi, E.; Cappuzzo, F.; Calabro, L.; Tiseo, M.; Turci, D.; Gamucci, T.; Antonelli, P.; Morabito, A.; Chella, A.; Giannarelli, D.; Galetta, D. | 2019-01-01 | THE ONCOLOGIST | - | 1.01 Articolo in rivista | - |